Water

Water

SCHEMBL445436

CCCC[N+](CC)(CC)S(=O)(=O)NC(=O)O.[OH-]

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
GRK2 P25098 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL1827725 0.89
SCHEMBL2289756 0.87
Water SCHEMBL3635067 0.85
SCHEMBL2888595 0.82
SCHEMBL18480410 0.69 EPHX1 (0.32)
SCHEMBL29172471 0.68 CA12 (0.50) MEN1LMNAPOLBGRK2KMT2A
SCHEMBL5127346 0.66 CA2 (0.64) LMNA
Water SCHEMBL117889 0.66 EPHX1 (0.31)
SCHEMBL5874470 0.65 SLC22A1 (0.41)
SCHEMBL13017382 0.65 ATM (0.37) MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
WO-2010064219-A1 PROCESS FOR THE PREPARATION OF A NOVEL INTERMEDIATE FOR CASPOFUNGIN RANBAXY LABORATORIES LIMITED (IN) 2010-06-10 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
EP-0535968-B1 Cyclohexapeptidyl hydroxypropionitrile compounds MERCK & CO INC (US) 2003-05-14 EP disclosed
US-6268338-B1 USEFUL AS AN ANTIBIOTIC, ESPECIALLY AS AN ANTIFUNGAL AGENT OR AS AN ANTIPROTOZOAL AGENT. MERCK & CO., INC. 2001-07-31 US disclosed
US-6030944-A AS ANTIBIOTIC MERCK & CO., INC. (US) 2000-02-29 US disclosed
EP-0779895-B1 AN IMPROVED PROCESS FOR PREPARING SIDE CHAIN DERIVATIVES OF CYCLOHEXAPEPTIDYL LIPOPEPTIDES MERCK & CO INC (US) 1999-11-17 EP disclosed
US-5948753-A ANTIBIOTIC MERCK & CO., INC. (US) 1999-09-07 US disclosed
US-5939384-A ANTIBIOTICS AS ANTIFUNGAL COMPOUNDS AND ANTIPROTOZOA AGENTS MERCK & CO., INC. (US) 1999-08-17 US disclosed
EP-0707488-A1 CYCLOHEXAPEPTIDYL AMINE COMPOUNDS MERCK & CO. INC. (US) 1996-04-24 EP disclosed
WO-1996008267-A1 SEMI-SYNTHETIC LIPOPEPTIDES, COMPOSITIONS CONTAINING SAID LIPOPEPTIDES, AND METHODS OF USE MERCK & CO., INC. (US) 1996-03-21 WO disclosed
EP-0701447-A1 CYCLOHEXAPEPTIDYL PROPANOLAMINE COMPOUNDS MERCK & CO. INC. (US) 1996-03-20 EP disclosed
WO-1996006109-A1 AN IMPROVED PROCESS FOR PREPARING SIDE CHAIN DERIVATIVES OF CYCLOHEXAPEPTIDYL LIPOPEPTIDES MERCK & CO., INC. (US) 1996-02-29 WO disclosed
WO-1994025048-A1 CYCLOHEXAPEPTIDYL AMINE COMPOUNDS MERCK & CO., INC. (US) 1994-11-10 WO disclosed
WO-1994025050-A1 CYCLOHEXAPEPTIDYL PROPANOLAMINE COMPOUNDS MERCK & CO., INC. (US) 1994-11-10 WO disclosed
US-5348940-A Fungicidal antibiotics MERCK & CO., INC. (US) 1994-09-20 US disclosed
EP-0535968-A1 Cyclohexapeptidyl hydroxypropionitrile compounds MERCK & CO. INC. (US) 1993-04-07 EP disclosed
EP-0535959-A1 Cyclohexapeptidyl propanolamine compounds MERCK & CO. INC. (US) 1993-04-07 EP disclosed
EP-0535967-A2 Cyclohexapeptidyl bisamine compounds MERCK & CO. INC. (US) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 MEN1 540/4885LMNA 1804/4885POLB 2797/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 MEN1 540/4885LMNA 1804/4885POLB 2797/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 MEN1 540/4885LMNA 1804/4885POLB 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.